The anti-COVID-19 drug developed by DRDO (Defence Research and Development Organization) named 2-deoxy-D-glucose which has been given the permission to be used in emergency by DCGI was first studied by Patanjali researchers, claimed Acharya Balkrishna.
On Sunday, a day after the drug was granted permission, Balkrishna tweeted, “We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.”
On Patanjali studied
He tweeted this with a picture of his research paper, co-authored with 3 other researchers. On this, Swami Ramdev said, “Proud of Patanjali being the first in every research on COVID-19.”
This drug is developed by INMAS in collaboration with DRL. In the first wave of covid, INMAS-DRDO scientists conducted experiements with CCMB’s help in which they discovered that this molecule works against the Coronavirus and stops its growth. Based on that, they were permitted for a Phase-2 trial.
Phase-2 trial was conducted on 110 patients and it took about 6 months in which the drug was found to be safe on COVID-19 patients.